Please login to the form below

Orencia

This page shows the latest Orencia news and features for those working in and with pharma, biotech and healthcare.

Opdivo drives growth at BMS, but US sales slow down

Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia

Latest news

Opdivo drives gain in BMS sales, but business revamp coming

Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.
Shire gives up on Momenta-partnered Humira biosimilar

It also has a biosimilar collaboration with generics giant Mylan covering six biologics, headed by M834, a biosimilar version of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacept).
Mylan buys into six biosimilars, including Orencia candidate

Mylan buys into six biosimilars, including Orencia candidate. Deal with Momenta bolsters biosimilars pipeline for new products. ... The agreement gives Mylan the rights to six biosimilars in Momenta's pipeline, including a version of Bristol-Myers
NICE backs four treatments for juvenile idiopathic arthritis

NICE backs four treatments for juvenile idiopathic arthritis. Includes BMS' Orencia and AbbVie's Humira. ... The institute backed Bristol-Myers Squibb's Orencia (abatacept), AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept) and Roche's RoActemra
NICE backs biosimilars in rheumatoid arthritis guidance

Orencia (abatacept) and MSD/J&J's Remicade (infliximab).

More from news
Approximately 10 fully matching, plus 33 partially matching documents found.

Latest Intelligence

Deal Watch January 2016

255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept).
Biosimilars - the same, but different?

Orencia and Actemra for rheumatoid arthritis.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

BMS’ Brian Daniels to retire

Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Brand leaders in RA will lose market share, predict rheumatologists

market leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Home based, Editorial Team Leader, Medical Communications: Excellent package

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Client Services Director – Healthcare Advertising - London: Neg

Delivery Manager/ Head of Delivery – Executive Search: Neg

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Client Services Director - Med Comms: Great salary and bebefits

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Account Manager: Competitive salary commensurate with experience

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Editorial Director – Medical Education (MedComms): Neg

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Business Unit Head, Medical Communications, London: Excellent package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Home based, Chief Medical Writer, Medical Communications: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....